Main clinical and hematologic characteristics of the 317 cases of CCgR, at diagnosis and before any treatment
| Age (y) | Mean ± SD | 47.4 ± 13.0 |
| Median (range) | 49.0 (9-73) | |
| Gender | male, no. of cases | 180 (57%) |
| Spleen | Palpable, no. of cases | 133 (43%) |
| Spleen (cm from costal margin) | Mean ± SD | 6.2 ± 5.1 |
| Median (range) | 4.0 (1-24) | |
| Hemoglobin (g/L) | Mean ± SD | 126 ± 19 |
| Median (range) | 127 (55-166) | |
| WBC count (× 109/L) | Mean ± SD | 98 ± 95 |
| Median (range) | 66 (12-471) | |
| Platelet count (× 109/L) | Median (range) | 325 (81-3264) |
| Platelet count (greater than 1500 × 109/L) | No. of cases | 4 (1%) |
| Myeloblasts (%) | Mean ± SD | 1.0 ± 2.2 |
| Median (range) | 0 (0-25.0) | |
| Eosinophils (%) | Mean ± SD | 2.1 ± 2.2 |
| Median (range) | 2.0 (0-15.0) | |
| Basophils (%) | Mean ± SD | 3.3 ± 3.4 |
| Median (range) | 2.2 (0-23.0) | |
| Basophils (at least 3%) | No. of cases | 148 (47%) |
| Transcript | b2a2 | 51 (16%) |
| b3a2 ± b2a2 | 110 (35%) | |
| Not known | 156 (49%) | |
| Sokal score (no. cases) | Less than 0.8 (low risk) | 179 (62%) |
| 0.8-1.2 (intermediate risk) | 76 (26%) | |
| Greater than 1.2 (high risk) | 35 (12%) | |
| Euro score (no. of cases) | At most 780 (low risk) | 164 (58%) |
| 781-1479 (intermediate risk) | 101 (36%) | |
| At least 1480 (high risk) | 16 (6%) | |
| Age (y) | Mean ± SD | 47.4 ± 13.0 |
| Median (range) | 49.0 (9-73) | |
| Gender | male, no. of cases | 180 (57%) |
| Spleen | Palpable, no. of cases | 133 (43%) |
| Spleen (cm from costal margin) | Mean ± SD | 6.2 ± 5.1 |
| Median (range) | 4.0 (1-24) | |
| Hemoglobin (g/L) | Mean ± SD | 126 ± 19 |
| Median (range) | 127 (55-166) | |
| WBC count (× 109/L) | Mean ± SD | 98 ± 95 |
| Median (range) | 66 (12-471) | |
| Platelet count (× 109/L) | Median (range) | 325 (81-3264) |
| Platelet count (greater than 1500 × 109/L) | No. of cases | 4 (1%) |
| Myeloblasts (%) | Mean ± SD | 1.0 ± 2.2 |
| Median (range) | 0 (0-25.0) | |
| Eosinophils (%) | Mean ± SD | 2.1 ± 2.2 |
| Median (range) | 2.0 (0-15.0) | |
| Basophils (%) | Mean ± SD | 3.3 ± 3.4 |
| Median (range) | 2.2 (0-23.0) | |
| Basophils (at least 3%) | No. of cases | 148 (47%) |
| Transcript | b2a2 | 51 (16%) |
| b3a2 ± b2a2 | 110 (35%) | |
| Not known | 156 (49%) | |
| Sokal score (no. cases) | Less than 0.8 (low risk) | 179 (62%) |
| 0.8-1.2 (intermediate risk) | 76 (26%) | |
| Greater than 1.2 (high risk) | 35 (12%) | |
| Euro score (no. of cases) | At most 780 (low risk) | 164 (58%) |
| 781-1479 (intermediate risk) | 101 (36%) | |
| At least 1480 (high risk) | 16 (6%) | |
Spleen size is given in centimeters as the maximum distance from costal margin, in the cases where the spleen was palpable (zero values are excluded from the calculation of the mean and the median). Myeloblasts, eosinophils, and basophils are in peripheral blood. The Sokal and Euro risk groups are identified as described in “Patients, materials, and methods” and Table 2. In some cases, the data were not avaiable (spleen, 7 cases; myeloblasts, 13 cases; eosinophils, 22 cases; basophils, 17 cases; Sokal, 27 cases; Euro, 36 cases).